Group 1 - The core viewpoint of the news is that Huabang Health has shown a positive stock performance with a 4.60% increase year-to-date and a significant rise in net profit for the first nine months of 2025 [1][2]. - As of January 13, Huabang Health's stock price reached 5.00 CNY per share, with a market capitalization of 9.9 billion CNY and a trading volume of 1.26 billion CNY [1]. - The company reported a revenue of 9.086 billion CNY for the first nine months of 2025, reflecting a year-on-year growth of 1.98%, while the net profit attributable to shareholders increased by 35.37% to 612 million CNY [2]. Group 2 - Huabang Health's main business segments include agricultural chemicals (58.03% of revenue), pharmaceuticals (27.61%), tourism services (9.00%), and medical services (3.24%) [1]. - The company has distributed a total of 4.909 billion CNY in dividends since its A-share listing, with 1.265 billion CNY distributed over the past three years [3]. - As of September 30, 2025, the number of shareholders decreased by 1.97% to 72,400, while the average number of circulating shares per person increased by 2.01% to 25,997 shares [2][3].

Group 1 - The company held its first extraordinary general meeting of shareholders in 2026 on January 12, with a total of 397 shareholders (or their proxies) present, representing 553,340,684 shares, which is 27.9476% of the total voting shares [5][6] - The meeting adopted several resolutions, including the approval of credit limits and guarantees for the company and its subsidiaries for the year 2026, with 95.4488% of the votes in favor [6][7] - The meeting also approved the increase of expected related party transactions for 2025 and 2026, with 91.0365% of the votes in favor [7] Group 2 - The company approved a proposal for forward foreign exchange settlement and RMB foreign exchange options for 2026, with 98.5345% of the votes in favor [8] - The meeting passed a resolution to amend the Independent Director Work System, with 95.6379% of the votes in favor [9] - The company also approved the revision of the External Guarantee Management System, with 95.6179% of the votes in favor [10] Group 3 - The company approved the revision of the Related Party Transaction Decision-Making System, with 95.6397% of the votes in favor [11] - The meeting adopted a resolution to amend the Management Measures for the Use of Raised Funds, with 95.6406% of the votes in favor [12] - The company approved the conditions for a non-public issuance of technology innovation exchangeable bonds, with 98.5676% of the votes in favor [14] Group 4 - The company approved the specific proposals related to the issuance of exchangeable bonds, including types, scale, and terms, with significant majorities in favor for each item [15][16][17][18] - The meeting authorized the board of directors to handle all matters related to the non-public issuance of technology innovation exchangeable bonds, with 98.5527% of the votes in favor [34] - The legal opinion from Beijing Times Jiuhua Law Firm confirmed that the meeting's procedures complied with relevant laws and regulations [35]

公司近日发布公告称，于2026年1月12日召开2026年第一次临时股东会，审议通过了关于公司及子公司 2026年度向银行等金融机构申请授信额度及担保事项、增加2025年度日常关联交易预计及预计2026年度 日常关联交易、开展远期结售汇业务和人民币对外汇期权组合业务、修订多项内部制度、非公开发行科 技创新可交换公司债券相关议案及授权董事会办理相关事宜等议案。会议表决结果均显示议案获通过， 无否决议案情形，股东会召集和召开程序合法合规。 截至2026年1月12日收盘，华邦健康（002004）报收于4.9元，较前一交易日上涨0.2%，最新总市值为 97.02亿元。该股当日开盘4.87元，最高4.93元，最低4.84元，成交额达1.66亿元，换手率为1.81%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《北京市时代九和律师事务所关于华邦生命健康股份有限公司2026年第一次临时股东会的法律意 见书》 《2026年第一次临时股东会决议公告》 最新公告列表 ...

（编辑 任世碧） 证券日报网讯 1月12日，华邦健康发布公告称，公司2026年第一次临时股东会审议通过《关于公司及子 公司2026年度向银行等金融机构申请授信额度及担保事项的议案》《关于增加2025年度日常关联交易预 计及预计2026年度日常关联交易的议案》《关于预计2026年度开展远期结售汇业务和人民币对外汇期权 组合等业务的议案》等多项议案。 ...

关于华邦生命健康股份有限公司 2026 年第一次临时股东会的法律意见书 北京市时代九和律师事务所 关于华邦生命健康股份有限公司 2026 年第一次临时股东会的法律意见书 致：华邦生命健康股份有限公司 北京市时代九和律师事务所（以下简称"本所"）根据华邦生命健康股份有限 公司（以下简称"贵公司"）的委托，指派律师出席贵公司 2026 年第一次临时股东 会（以下简称"本次股东会"）。本所律师依据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）《上市公司股东会规则》（以 下简称"《股东会规则》"）、其他相关法律、法规、规范性文件以及《华邦生命 健康股份有限公司章程》（以下简称"《公司章程》"）的有关规定，出具本法律 意见书。 本所及经办律师依据《证券法》、《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具日以 前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原 则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完整， ...

华邦生命健康股份有限公司 2026年第一次临时股东会决议公告 证券代码：002004 证券简称：华邦健康 公告编号：2026002 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无否决议案的情形； 3、召开方式：本次股东会采用现场表决与网络投票相结合的方式召开，公 司股东应选择现场投票、网络投票中的一种方式，如果同一表决权出现重复投票 表决的，以第一次投票表决结果为准。 4、召集人：公司董事会 2、本次股东会不涉及变更前次股东会决议。 一、会议召开和出席情况 1、会议召开的时间： （1）现场会议召开时间：2026 年 1 月 12 日（星期一）下午 14:00； （2）网络投票时间：2026 年 1 月 12 日。其中，通过深圳证券交易所交易 系统进行网络投票的具体时间为 2026 年 1 月 12 日 9:15—9:25、9:30—11:30 和 13:00—15:00；通过深圳证券交易所互联网投票的具体时间为 2026 年 1 月 12 日 9:15—15:00 期间的任意时间。 2、现场会议召开地点：重庆市渝北区人和星光大道 ...

Group 1 - The company has received notification from its controlling shareholder, Chongqing Huibang Zhuoyuan Technology Co., Ltd., regarding the pledge extension of part of its shares [1] - As of the announcement date, the cumulative pledge situation of shares held by Huibang Zhuoyuan and its concerted actors, including Mr. Zhang Songshan, Mr. Zhang Yizhuo, and Ms. Zhao Danlin, is detailed [1] - The announcement includes reference documents such as the stock pledge repurchase agreement, account statements, and a detailed list of securities pledges and judicial freezes issued by China Securities Depository and Clearing Corporation Limited [1]

1 证券代码：002004 证券简称：华邦健康 公告编号：2026001 华邦生命健康股份有限公司 关于控股股东部分股份质押展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）于近日接到公司控股股东 重庆汇邦卓远科技有限公司（以下简称"汇邦卓远"）的通知，获悉其将所持有 本公司的部分股份办理质押展期业务,具体情况如下： 二、汇邦卓远及其一致行动人股份累计质押基本情况 截至本公告披露日，汇邦卓远及其一致行动人张松山先生、张一卓先生、赵 丹琳女士所持股份质押情况如下： | | | | | | 占公司 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 持股数量 （股） | 持股比例 | 累计质押数量 （股） | 占其所持 股份比例 | 总股本 | 已质押股份 | 占已质 | 未质押股份 | 占未质 | | | | | | | 比例 | 限售和冻结 | 押股份 | 限售和冻结 ...

Core Viewpoint - Huabang Health (002004) is actively engaging in financial maneuvers, including a non-public issuance of convertible bonds and increasing its credit lines, to manage its debt and enhance operational liquidity [2][7]. Trading Information Summary - As of December 23, 2025, Huabang Health's stock closed at 4.83 yuan, down 0.62%, with a turnover rate of 1.01%, trading volume of 190,000 shares, and a transaction value of 91.92 million yuan [1]. - On the same day, the net inflow of funds from major investors was 446,680 yuan, while retail investors experienced a net outflow of 491,300 yuan [1]. Company Announcements Summary - The company announced a non-public issuance of convertible bonds not exceeding 1 billion yuan, with a term of up to 3 years, aimed at repaying interest-bearing debts [2]. - The board approved the application for a total credit line of up to 13.154 billion yuan for 2026, with a guarantee limit of 10.274 billion yuan [7]. - The company plans to conduct forward foreign exchange settlement and RMB foreign exchange options trading in 2026, with a total transaction limit of up to 41 million USD to mitigate exchange rate risks [5][6]. Related Transactions Summary - The company approved an increase in expected daily related transactions for 2025, totaling approximately 138.18 million yuan, and for 2026, expected related transactions amount to 1.199 billion yuan, involving multiple related parties [4]. - The pricing of related transactions will be based on market fair prices to ensure the company's independence [4]. Internal Control and Governance Summary - The company revised its independent director work system to ensure independence and proper governance, emphasizing the need for independent opinions on related transactions [7]. - The company has established a management system for the use of raised funds, ensuring that funds are used specifically for designated purposes and not for financial investments [8]. - The company has implemented a decision-making system for related transactions, detailing approval processes and disclosure requirements [9].

Core Viewpoint - Huabang Health (002004) is planning a non-public issuance of technology innovation exchangeable bonds to raise up to 1 billion RMB for debt repayment and other legal purposes [1] Group 1: Stock Performance - As of December 23, 2025, Huabang Health closed at 4.83 RMB, down 0.62% from the previous trading day [1] - The stock opened at 4.85 RMB, reached a high of 4.88 RMB, and a low of 4.81 RMB, with a trading volume of 91.92 million RMB and a turnover rate of 1.01% [1] Group 2: Bond Issuance - The company’s board approved a plan for a non-public issuance of technology innovation exchangeable bonds, targeting professional institutional investors [1] - The bond issuance will not exceed 1 billion RMB and will have a term of no more than 3 years, with the option to exchange for shares of Shandong Kaisheng New Materials Co., Ltd. [1] - The raised funds, after deducting issuance costs, will be used for repaying interest-bearing debts and other purposes compliant with legal regulations [1] - The issuance plan is subject to approval by the shareholders' meeting [1]